A Phase II Pilot Clinical Trial of Lurbinectedin in Patients With Advanced Pancreatic Cancer With DNA Repair Mutations
The purpose of this phase II trial is to evaluate the safety and efficacy of lurbinectedin (PM01183) in patients with advanced pancreatic cancer with DNA repair mutations.
Study ID: HRI-Lurbinectedin-001
Trial Phase: Phase II
Trial Sponsor: HonorHealth Research Institute
Therapies Used in This Trial: Lurbinectedin